OvaScience, Inc.
OvaScience, Inc. is listed today as Tempest Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2026 | $8 M | Private placement after listing | $2 to $10 million | options | SEC | |
| May 2026 | $4 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Mar 2026 | $2 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Apr 2022 | $15 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Mar 2013 | $35 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jun 2012 | $5 M | No. 2 | $2 to $10 million | equity | SEC | |
| Mar 2012 | $37 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
OvaScience, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).
SEC Form D · Oct 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2026
That is all the official record says: OvaScience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of OvaScience, Inc. are on record.
Investors#
11 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bessemer Venture Partners VII Institutional L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Bessemer Venture Partners VII L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| BVP VII Special Opportunity Fund LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Deer Management Co. LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Deer VII & Co. L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Deer VII & Co. Ltd. | Company | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| GC Entrepreneurs Fund V, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| General Catalyst GP V, LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| General Catalyst Group V LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| General Catalyst Partners V, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Longwood Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 253 investors.
Largest shareholders today
Institutions holding Tempest Therapeutics, Inc. shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$0 M1.17%
- Geode Capital Management, LLC$0 M0.37%
- Vanguard Fiduciary Trust Co$0 M0.34%
- BlackRock, Inc.$0 M0.20%
- UBS Group AG$0 M0.13%
- HRT Financial LP$0 M0.11%
- Northern Trust Corp$0 M0.10%
- Citigroup Inc$0 M0.08%
- StoneX Group Inc.$0 M0.07%
- Vanguard Personalized Indexing Management, LLC$0 M0.06%
- TRB Wealth Management, LLC$0 M0.05%
- Nuveen, LLC$0 M0.03%
- Tower Research Capital LLC (TRC)$0 M0.02%
- Morgan Stanley$0 M0.01%
- Osaic Holdings, Inc.$0 M0.01%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Constance Ames | Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary | Oct 2026 |
| Justin Trojanowski | Vice President, Finance, Principal Financial Officer and Corporate Secretary | Jun 2026 |
| Matthew Angel | President and Chief Executive Officer | Jun 2026 |
| Nicholas Maestas | Executive officer | Apr 2026 |
| Stephen R. Brady | Executive officer | May 2022 |
| Thomas W. Dubensky | Executive officer | May 2022 |
| Alison A. Lawton | Executive officer | Mar 2013 |
| Christopher A. Bleck | Executive officer | Mar 2013 |
| Michelle Dipp | Executive officer | Mar 2013 |
| Scott A. Chappel | Executive officer | Mar 2013 |
| Michael A. Flanagan | Executive officer | Apr 2012 |
| John Wilbert Frederick | Director | Oct 2026 |
| Nancy Freda-Smith | Director | Oct 2026 |
| John David Yee | Director | Jun 2026 |
| Matthew Angel | President and Chief Executive Officer | Jun 2026 |
| William Drake Richey | Director | Jun 2026 |
| Christine Pellizzari | Director | Apr 2026 |
| Michael Raab | Director | Apr 2026 |
| Ronit Simantov | Director | Apr 2026 |
| Stephen Brady | Director | Apr 2026 |
| Christine W. Pellizzari | Director | May 2022 |
| Geoffrey W. Nichol | Director | May 2022 |
| Michael W. Raab | Director | May 2022 |
| Ronit W. Simantov | Director | May 2022 |
| Stephen R. Brady | Director | May 2022 |
| Thomas W. Dubensky | Director | May 2022 |
| Thomas W. Woiwode | Director | May 2022 |
| Christoph A. Westphal | Director | Mar 2013 |
| Harald A. Stock | Director | Mar 2013 |
| Jeff A. Capello | Director | Mar 2013 |
| Jonathan A. Tilly | Director | Mar 2013 |
| Michelle Dipp | Director | Mar 2013 |
| Richard A. Aldrich | Director | Mar 2013 |
| Stephen A. Kraus | Director | Mar 2013 |
| Thomas A. Malley | Director | Mar 2013 |
| John A. Simon | Director | Aug 2012 |
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.